The pharmaceutical and medical industry contributes about 900 billion euros to the gross domestic product of the People’s Republic of China. This corresponds to about 8.5 percent. Tu Yongrui, CEO of Changzhou Siyao, is proud of the important role the company plays in this market.
Changzhou Siyao supports global enterprises in the development and introduction of their pharmaceuticals and health products to the Chinese market. “We specialize in the production of pharmaceuticals in new dosage forms and various medical fields,” explains Tu Yongrui. Siyao’s extensive product portfolio includes, among other things, orally dissolving film strips (ODF), the great clinical benefit of which is emphasized by the Managing Director: “ODFs are superior to other dosage forms in many ways, including their ease of use and the quick release and dispersal of the active ingredient.”
Tu Yongrui regards the market opportunities of this administration form as very attractive: “Particularly in pediatrics and geriatrics, we see a huge potential for easy-to-administer drugs.” Like all industrialized countries, China is also experiencing demographic change. In the case of the People’s Republic with their 1.39 billion people, however, the population proportions reach enormous dimensions: While today some 220 million Chinese are elderly, the number will rise to 480 million by 2050. The proportion of children in 2017 was 300 million.
Extensive fields of application
While they administer drugs in a well-tolerated manner, ODFs not only facilitate the life of children and the elderly: “We are continuously working to develop new products for the treatment of chronic diseases such as asthma and allergies, as well as cardiovascular, digestive or mental diseases,” says Tu Yongrui.
“Particularly in pediatrics and geriatrics, we see a huge potential for easy-to-administer drugs.”Tu Yongrui, CEO of Changzhou Siyao
Siyao is also active in other fields. For example, Harro Höfliger has delivered a wide variety of process solutions to Changzhou. In addition to web processing lines used for ODF production or transdermal patches, the Chinese company also purchased machines for capsule filling.
In the future, the company would like to devote even more attention to the healthcare segment and appreciates having a “versatile partner such as Harro Höfliger” at their side who “always addresses customer product requirements”.
About Changzhou Siyao
Changzhou Siyao Pharmaceuticals Co. Ltd. with headquarters in Changzhou, northwest of Shanghai, is among the Top 100 Chinese pharmaceutical enterprises. Their core business areas are the development, production and marketing of ready-to-use dosage forms in various fields of application. Siyao is approved and certified by the American FDA and the Chinese CEP as well as the Japanese Health Ministry. With 500 employees, Changzhou Siyao generated a turnover of about 330 million euros in 2017.
Photos: shutterstock.com/Alexandra_Strekoza, Changzhou Siyao